We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

141 hedge funds and large institutions have $973M invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2014 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 50 increasing their positions, 41 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

504% more call options, than puts

Call options by funds: $27.9M | Put options by funds: $4.61M

121% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 19

22% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 41

19% more funds holding

Funds holding: 118141 (+23)

12% more capital invested

Capital invested by funds: $869M → $973M (+$104M)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

Holders
141
Holders Change
+23
Holders Change %
+19.49%
% of All Funds
4.04%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.2%
New
42
Increased
50
Reduced
41
Closed
19
Calls
$27.9M
Puts
$4.61M
Net Calls
+$23.2M
Net Calls Change
-$10.2M

HZNP Hedge Fund Activity: Q2 2014 in Review

141 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2014, worth a combined $973M — up 12% from $869M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new HZNP positions and 19 closed out — a net gain of 23 holders — while 50 added to existing stakes and 41 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $38.5M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $16.1M sold.

  • 141 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2014, up from 118 in Q1 2014.
  • Funds reported $973M of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2014, up 12% quarter-over-quarter.
  • 42 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2014 and 19 closed out, a net change of +23 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2014 was HealthCor Management, an estimated $38.5M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2014 was Oxford Asset Management, an estimated $16.1M sold.

Based on aggregated 13F filings for Q2 2014.